Purchase Short-Term Access
Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors
Michael Farkouh, MD, MSc
Annals of Internal Medicine 2010;152:JC6-10.
doi:10.7326/0003-4819-152-12-201006150-02010
Purchase Online access to this article for 24 hours
